Navigation Links
New target for the fight against cancer as a result of excessive blood vessel formation
Date:8/3/2013

New blood vessel formation (angiogenesis) stimulates the growth of cancer and other diseases. Anti-angiogenic inhibitors slow down cancer growth by disrupting the blood supply to the tumor. To date, the success of these treatments is limited by resistance, poor efficiency and harmful side effects. In the leading scientific journal Cell, Peter Carmeliet (VIB-KU Leuven) and his team reported that sugar metabolism (a process that we call glycolysis) also plays an essential role in the formation of new blood vessels. These totally revolutionary insights open up many new therapeutic opportunities for the treatment of cancer and diseases as a result of excessive blood vessel formation.

Every growing cell in our body is provided with oxygen and nutrients via our blood vessels.

Blood vessels are formed by endothelial cells which line the inside wall of the vessel. These cells require energy to be able to form new blood vessels. However, it was not known how these cells produced the required energy and it was never considered to inhibit the energy production process in order to block angiogenesis.

Under the guidance of Peter Carmeliet, a team consisting of Katrien De Bock, Maria Georgiadou and Sandra Schoors discovered that glycolysis is the most important mechanism for endothelial cells to supply energy for blood vessel formation. Peter Carmeliet and his team demonstrated that endothelial cells can be paralyzed by blocking glycolysis and consequently stop to form blood vessels. This is the first evidence that starvation of endothelial cells could offer new therapeutic opportunities for the treatment of excessive angiogenesis in diseases (like cancer).

Peter Carmeliet: "Our discovery opens up a whole new domain for inhibition of angiogenesis in various diseases such as cancer. Endothelial cells need nutrients and energy for growth and if you take away their energy, you can prevent them from forming new blood vessels".


'/>"/>

Contact: Kris Van der Beken
kris.vanderbeken@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology technology :

1. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
2. Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
3. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
4. DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks
5. Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets
6. Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
7. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
8. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
9. Surefire Medical Launches Next Generation Infusion System ST-LT and Specialty Catheters at SIR - Maximizing Targeted Delivery of Embolics Without Reflux
10. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
11. Targeting T cells in rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... NY (PRWEB) , ... January 20, 2017 , ... Nipro ... a Joint Venture (JV) under which Nipro will receive exclusive marketing and sales rights ... to establish best practices for hemodialysis patients in Japan, the new Nipro - Transonic ...
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... Kan. , Jan. 20, 2017 Aratana ... therapeutics company focused on the licensing, development and commercialization ... Animal Pharm,s Best Company in North ... granted the award based on the FDA ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) ...
(Date:1/20/2017)... ... 2017 , ... The two newest companies to join the University City Science ... out from The Wistar Institute, and Sanguis, launched by a trio of students from ... , Vironika is developing a treatment for a chronic viral infection and its associated ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... --  IdentyTechSolutions America LLC , a leading provider ... a cutting-edge manufacturer of software and hardware security ... integrated solutions that comprise IDT biometric readers and ... IdentyTech,s customers with combined physical identification and anti-tailgating ... theft. "We are proud to use ...
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical device ... billion by 2021 from USD 5.31 billion in 2016, at a ... ... driven by technological advancements in medical devices, launch of a growing ... for wireless connectivity among healthcare providers, and increasing focus on physical ...
Breaking Biology News(10 mins):